Search - tctmd.com

Displaying 921 - 940 of 1067

Sort: Relevancy | Date

Presentation TCT 2016

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Presenter: Neil E. Moat, John G. Webb, Stephen R. Ramee

October 31, 2016

Presentation TCT 2016

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Presenter: Neil E. Moat, John G. Webb, Pieter R. Stella

October 31, 2016

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Presentation TCT 2016

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Presenter: Neil E. Moat, John G. Webb, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

Complications of Structural Heart Disease Intervention

Presenter: George S. Hanzel, Mauricio G. Cohen

October 31, 2016

Presentation TCT 2016

Case #2: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Augusto D. Pichard

October 31, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Complications That Can Occur After Transcatheter Mitral Valve Replacement

Presenter: Michael J. Mack, Ralph Stephan von Bardeleben, Neil E. Moat

October 31, 2016

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

Case #1: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Presenter: Raj Makkar, Lars Sondergaard, John G. Webb

October 31, 2016

Presentation TCT 2016

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Presenter: Raj Makkar, Lars Sondergaard, Helene Eltchaninoff

October 31, 2016

Presentation TCT 2016

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Presenter: Raj Makkar, Lars Sondergaard, A. Pieter Kappetein

October 31, 2016

Presentation TCT 2016

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Presenter: Raj Makkar, Lars Sondergaard, Ganesh Manoharan

October 31, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Advertisement

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Complications of Structural Heart Disease Intervention

Case #2: A TAVR Complication to Learn From

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Complications That Can Occur After Transcatheter Mitral Valve Replacement

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Case #1: A TAVR Complication to Learn From

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Controversy 4. Will the Minimalist Strategy Dominate TAVR in the Future: Supportive Clinical and Economic Data

Late (>5 years) Clinical and Echo Outcomes After TAVR II: The Vancouver Experience

Late (>5 years) Clinical and Echo Outcomes After TAVR I: The Rouen Experience

Controversy 3. Surgical Perspectives on Late Bioprosthetic Valve Durability

Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy!

Flash Debate: Point 4D-CT Leaflet Thickening Is an Imaging Curiosity With No Clinical Relevance!

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content